


SMI's 2nd Annual AI in Drug Discovery Announces key industry speakers and agenda released

SMI's Group 2nd Annual AI in Drug Discovery is taking place on 15th-16th March 2021 as a virtual conference and sponsored by OpenEye Scientific Software.



LONDON, LONDON, UNITED KINGDOM, November 20, 2020 /EINPresswire.com/ -- This year's event will delve into the [latest innovations in machine learning for enhancing discovery pipelines](#). Furthermore the two-day virtual conference will focus on 4 key themes: machine learning and automation for improved drug discovery pipelines; effective prediction of compound properties; data robustness and curation; innovative use of AI for rare and undruggable diseases, and will highlight key case studies across these themes, uncovering key developments in pharma of data optimization and to aid therapeutic discovery. Real-world examples of AI in structure-based drug design and patient relevant data will be explored in eye-opening detail.

SMI Group is proud to announce the [chair for the conference](#) Darren Green, Director of Molecular Design & Senior Fellow, GSK

Key [Expert Speakers](#) include:

- Noor Shaker, CEO, GlamorousAI
- Maria Luisa Pineda, Co-Founder & CEO, Envisagenics
- Ed Addison, Co-founder, Chairman & CEO, Cloud Pharmaceuticals
- Diling Warren, Director, Head of Translational Medicine Statistics, Teva Pharmaceuticals
- Lili Peng, Associate Director Scientific Ecosystem Analytics Lead, Biogen
- Mark De Pristo, CEO, BigHat Biosciences
- Philippe Moingeon, Head of Immuno-inflammation, Servier
- Hugo Ceulemans, Scientific Director, Discovery Data Sciences, Janssen
- Peter Henstock, Machine Learning & AI Lead, Pfizer
- Naheed Kurji, CEO, Cyclica

To view the full speaker line-up and 2-day agenda please click on this link <http://www.ai-indrugdiscovery.com/PR1>

Key highlights for the 2021 conference include, discovering the latest innovations in AI-based drug discovery platforms, engaging in case study presentations from leading pharma and biotech companies on machine learning and improved drug discovery pipelines, understanding how AI can be effectively implemented to enhance productivity, delving into best practices in data quality, curation, and validation and exploring how AI is being used to unlock therapies that have evaded traditional drug discovery.

If you are interested in participating and attending the conference, you can register your free place at <http://www.ai-indrugdiscovery.com/PR1>.

Are you interested in sponsoring, exhibiting or speaking at this event, contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

SMI's 2nd Annual AI in Drug Discovery Conference 2021

15 & 16 March 2021

Virtual Conference: Online Access Only

<http://www.ai-indrugdiscovery.com/PR1>

Follow us @SMiPharm

#SMiAlinDrugDis

---- END ----

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Simi Sapal

SMi Group

[email us here](#)

+442078276000

This press release can be viewed online at: <https://www.einpresswire.com/article/531153757>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

